title: Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: correlation to pathologic predictors.
abstract: OBJECTIVE
  The objective of this study was to examine the association of EZH2 and paxillin expression and DNA ploidy status with pathological parameters of breast cancer, aiming to correlate tumor phenotype with its malignant behavior.
  
  
  METHODS
  EZH2 and paxillin expression and DNA ploidy were evaluated in imprint smear samples obtained from 105 breast tumors after surgical removal.
  
  
  RESULTS
  Increased expression of paxillin was associated with p53 expression (p=0.005), Ki-67 expression (p=0.018) and EZH2 expression (p<0.0001). EZH2 expression correlated with estrogen receptor (ER) and progesterone receptor (PR) status (p=0.01 and p=0.035, respectively), and expression of p53 and Ki-67 (p=0.007 and p<0.0001, respectively). Aneuploid tumors were significantly correlated with poor differentiation (p=0.000), stage of disease (p=0.000), size of the primary tumor (p=0.015), presence of nodal metastasis (p=0.001), ER status (p=0.008), cerbB2 status (p=0.012), and expression of Ki-67 (p=0.001) and EGFR (p=0.018). Multivariate analysis of ploidy results using paxillin and EZH2 expression as dependent variables revealed that aneuploid tumors were associated with disease stage and grade of differentiation, cerbB2 expression and EZH2 expression.
  
  
  CONCLUSIONS
  Our results show that aneuploid tumors, EZH2 expression and paxillin expression correlate with more aggressive phenotype of breast cancer.
authors.affiliation: Breast Unit, Iaso General Hospiral, Athens, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Panousis
authors.forename: G
authors.initials: G
authors.lastname: Xepapadakis
authors.forename: E
authors.initials: E
authors.lastname: Lagoudianakis
authors.forename: G
authors.initials: G
authors.lastname: Karavitis
authors.forename: N
authors.initials: N
authors.lastname: Salemis
authors.forename: N
authors.initials: N
authors.lastname: Koronakis
authors.forename: E
authors.initials: E
authors.lastname: Patsouris
authors.forename: D
authors.initials: D
authors.lastname: Koronarchis
authors.forename: D
authors.initials: D
authors.lastname: Grosomanidis
authors.forename: G
authors.initials: G
authors.lastname: Chryssikos
authors.forename: P
authors.initials: P
authors.lastname: Ntasiou
authors.forename: V
authors.initials: V
authors.lastname: Kyriakidou
authors.forename: A M
authors.initials: AM
authors.lastname: Athanassiadou
authors.forename: P
authors.initials: P
authors.lastname: Athanassiadou
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000235:genetics* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry* / Q000235:genetics* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000737:chemistry* / Q000235:genetics* / Q000473:pathology; D002454:Cell Differentiation; D016009:Chi-Square Distribution; D000071221:Enhancer of Zeste Homolog 2 Protein; D005260:Female; D006801:Humans; D016015:Logistic Models; D008207:Lymphatic Metastasis; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D051419:Paxillin / Q000032:analysis*; D010641:Phenotype; D011003:Ploidies; D063151:Polycomb Repressive Complex 2 / Q000032:analysis*; D011379:Prognosis; D012307:Risk Factors; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor; C496061:PXN protein, human; D051419:Paxillin; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2